Showing results (151-160 of 158) with videos related to
Sort By:
Pageof 16
You have reached the last page of results.This site can display upto 158 results.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|September 11, 2020
Refined Stratification Based on Baseline Concomitant Mutations and Longitudinal Circulating Tumor DNA Monitoring in Advanced EGFR-Mutant Lung Adenocarcinoma Under Gefitinib TreatmentJianchun Duan, JiaChen Xu, Zhijie Wang, et al.Nanoscale|April 9, 2025
Synthesis and electronic structure of atomically thin 2H-MoTe<sub>2</sub>Wenjuan Zhao, Xieyu Zhou, Dayu Yan, et al.Thoracic Cancer|September 26, 2018
Real-world EGFR testing in patients with stage IIIB/IV non-small-cell lung cancer in North China: A multicenter, non-interventional studyYing Cheng, Yan Wang, Jun Zhao, et al.Oncotarget|May 22, 2016
Tumor-selective replication herpes simplex virus-based technology significantly improves clinical detection and prognostication of viable circulating tumor cellsWen Zhang, Li Bao, Shaoxing Yang, et al.Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|June 6, 2022
Efficacy and Safety of Limertinib (ASK120067) in Patients With Locally Advanced or Metastatic EGFR Thr790Met-Mutated NSCLC: A Multicenter, Single-Arm, Phase 2b StudyYuankai Shi, Baolan Li, Lin Wu, et al.Eclinicalmedicine|November 29, 2021
Efficacy and safety of MIL60 compared with bevacizumab in advanced or recurrent non-squamous non-small cell lung cancer: a phase 3 randomized, double-blind studyRui Wan, Xiaorong Dong, Qun Chen, et al.Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|January 16, 2023
Camrelizumab Plus Carboplatin and Pemetrexed as First-Line Treatment for Advanced Nonsquamous NSCLC: Extended Follow-Up of CameL Phase 3 TrialCaicun Zhou, Gongyan Chen, Yunchao Huang, et al.Journal for Immunotherapy of Cancer|November 28, 2024
Camrelizumab plus carboplatin and pemetrexed as first-line therapy for advanced non-squamous non-small-cell lung cancer: 5-year outcomes of the CameL randomized phase 3 studyCaicun Zhou, Gongyan Chen, Yunchao Huang, et al.Pageof 16